Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
Saved in:
| Title: | Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. |
|---|---|
| Authors: | Venugopal S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shoukier M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Dinardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Marx KR; Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Popat UR; Department of Stem Cell Transplant, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shpall EJ; Department of Stem Cell Transplant, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kanagal-Shamanna R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. |
| Source: | Cancer [Cancer] 2021 Oct 01; Vol. 127 (19), pp. 3541-3551. Date of Electronic Publication: 2021 Jun 28. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1097-0142 |
|---|---|
| DOI: | 10.1002/cncr.33675 |
